NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route (Ascending) | Package Effective Date | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
70934-0101-21 | 70934-0101 | Prednisone | Prednisone | 5.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | April 16, 2018 | In Use | |
70934-0543-05 | 70934-0543 | Prednisone | PREDNISONE | 50.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Feb. 10, 2020 | April 30, 2023 | No Longer Used |
65597-0504-04 | 65597-0504 | QUIZARTINIB | VANFLYTA | 17.7 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | FLT3 | Oral | July 20, 2023 | In Use | |
65597-0504-28 | 65597-0504 | QUIZARTINIB | VANFLYTA | 17.7 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | FLT3 | Oral | July 20, 2023 | In Use | |
65597-0511-04 | 65597-0511 | QUIZARTINIB | VANFLYTA | 26.5 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | FLT3 | Oral | July 20, 2023 | In Use | |
65597-0511-28 | 65597-0511 | QUIZARTINIB | VANFLYTA | 26.5 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | FLT3 | Oral | July 20, 2023 | In Use | |
81864-0101-30 | 81864-0101 | Momelotinib | Ojjaara | 200.0 mg/1 | Chemotherapy | Enzyme Inhibitor | JAK 1/2 | Oral | Sept. 15, 2023 | In Use | |
81864-0102-30 | 81864-0102 | Momelotinib | Ojjaara | 150.0 mg/1 | Chemotherapy | Enzyme Inhibitor | JAK 1/2 | Oral | Sept. 15, 2023 | In Use | |
81864-0103-30 | 81864-0103 | Momelotinib | Ojjaara | 100.0 mg/1 | Chemotherapy | Enzyme Inhibitor | JAK 1/2 | Oral | Sept. 15, 2023 | In Use | |
00310-0512-28 | 00310-0512 | Acalabrutinib | Calquence | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BTK | Oral | April 1, 2018 | July 31, 2021 | In Use |
00310-0512-60 | 00310-0512 | Acalabrutinib | Calquence | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BTK | Oral | Oct. 31, 2017 | In Use | |
00310-0512-95 | 00310-0512 | Acalabrutinib | Calquence | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BTK | Oral | April 1, 2020 | July 31, 2025 | In Use |
43063-0706-30 | 43063-0706 | Estradiol | Estradiol | 1.0 mg/1 | Hormonal Therapy | Estrogen | Oral | Oct. 6, 2016 | Oct. 31, 2023 | In Use | |
43063-0706-90 | 43063-0706 | Estradiol | Estradiol | 1.0 mg/1 | Hormonal Therapy | Estrogen | Oral | Sept. 20, 2016 | Oct. 31, 2023 | In Use | |
43063-0717-30 | 43063-0717 | Estradiol | Estradiol | 2.0 mg/1 | Hormonal Therapy | Estrogen | Oral | Sept. 21, 2017 | Oct. 31, 2023 | In Use | |
43063-0717-90 | 43063-0717 | Estradiol | Estradiol | 2.0 mg/1 | Hormonal Therapy | Estrogen | Oral | Oct. 12, 2016 | Oct. 31, 2023 | In Use | |
50242-0210-12 | 50242-0210 | Pralsetinib | Gavreto | 100.0 mg/1 | Chemotherapy | Enzyme Inhibitor | RET, DDR1, TRKC, FLT3, JAK1/2, TRKA, VEGFR2, PDGFRB, FGFR1 | Oral | Sept. 28, 2022 | In Use | |
50242-0210-60 | 50242-0210 | Pralsetinib | Gavreto | 100.0 mg/1 | Chemotherapy | Enzyme Inhibitor | RET, DDR1, TRKC, FLT3, JAK1/2, TRKA, VEGFR2, PDGFRB, FGFR1 | Oral | July 1, 2021 | In Use | |
50242-0210-83 | 50242-0210 | Pralsetinib | Gavreto | 100.0 mg/1 | Chemotherapy | Enzyme Inhibitor | RET, DDR1, TRKC, FLT3, JAK1/2, TRKA, VEGFR2, PDGFRB, FGFR1 | Oral | July 1, 2021 | In Use | |
50242-0210-86 | 50242-0210 | Pralsetinib | Gavreto | 100.0 mg/1 | Chemotherapy | Enzyme Inhibitor | RET, DDR1, TRKC, FLT3, JAK1/2, TRKA, VEGFR2, PDGFRB, FGFR1 | Oral | Sept. 15, 2020 | Feb. 11, 2022 | In Use |
50242-0210-90 | 50242-0210 | Pralsetinib | Gavreto | 100.0 mg/1 | Chemotherapy | Enzyme Inhibitor | RET, DDR1, TRKC, FLT3, JAK1/2, TRKA, VEGFR2, PDGFRB, FGFR1 | Oral | July 1, 2021 | In Use | |
51862-0333-01 | 51862-0333 | Estradiol | Estradiol | 1.0 mg/1 | Hormonal Therapy | Estrogen | Oral | Aug. 3, 2016 | May 31, 2023 | In Use | |
51862-0333-05 | 51862-0333 | Estradiol | Estradiol | 1.0 mg/1 | Hormonal Therapy | Estrogen | Oral | Aug. 3, 2016 | Oct. 31, 2023 | In Use | |
51862-0334-01 | 51862-0334 | Estradiol | Estradiol | 2.0 mg/1 | Hormonal Therapy | Estrogen | Oral | Aug. 3, 2016 | Oct. 31, 2023 | In Use | |
51862-0334-05 | 51862-0334 | Estradiol | Estradiol | 2.0 mg/1 | Hormonal Therapy | Estrogen | Oral | Aug. 3, 2016 | Nov. 30, 2023 | In Use |
Found 10,000 results in 7 milliseconds — Export these results